Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Subject- and Evaluator-Masked, Phase 2 Clinical Trial Comparing EC-104 Intravitreal Implant to Ozurdex® for the Treatment of Diabetic Macular Edema (BETTIS-1)

NCT06536491 is registered in ClinicalTrials.gov with Eclipse Life Sciences, Inc. as lead sponsor.

NCT NCT06536491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06536491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Subject- and Evaluator-Masked, Phase 2 Clinical Trial Comparing EC-104 Intravitreal Implant to Ozurdex® for the Treatment of Diabetic Macular Edema (BETTIS-1)
Lead sponsor
Eclipse Life Sciences, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 19, 2024
Completion date
December 31, 2026
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema